Today, a Director at TrovaGene (NASDAQ: TROV), Stanley Tennant, bought shares of TROV for $8,000.
This recent transaction increases Stanley Tennant’s holding in the company by 4.42% to a total of $217.2K. In addition to Stanley Tennant, one other TROV executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on TrovaGene’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $100.1K and GAAP net loss of $4.79 million. In comparison, last year the company earned revenue of $95.04K and had a GAAP net loss of $10 million. Currently, TrovaGene has an average volume of 5,000.
Nine different firms, including BTIG and Deutsche Bank, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.
Read More on TROV:
